Changchun BCHT Biotechnology Co. (688276.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenCNY 15.35

From 52W high−13.31%

Volume9.70M

Market capCNY 6.71B

P/E (TTM)−25.6x

P/S (TTM)11.8x

Div yield—

Key dataSep 18, 2026

Open

CNY 15.35

From 52W high

−13.31%

Volume

9.70M

Market cap

CNY 6.71B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−38.7x

P/E (TTM)

−25.6x

RSI (14)

57.5

MomentumView details →

1D Return

−6.57%

YTD Return

—

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

−25.6x

EV/EBITDA

−38.7x

EV/Sales

11.9x

P/S (TTM)

11.8x

P/B (TTM)

1.8x

ProfitabilityView details →

Gross Margin

72.06%

Net Margin

−45.26%

EBITDA Margin

−30.88%

ROE (TTM)

−6.95%

ROA (TTM)

−5.21%

Asset Turnover

0.12x

GrowthView details →

Revenue YoY

−47.36%

EPS YoY

—

FCF YoY

+51.11%

Revenue CAGR 3Y

−17.34%

EPS CAGR 3Y

—

EBITDA YoY

—

MomentumView details →

1D Return

−6.57%

YTD Return

—

1Y Return

—

RSI (14)

57.5

vs 50D SMA

+7.58%

vs 200D SMA

—

Capital & dividendView details →

Debt/Equity

0.08x

Current Ratio

1.28x

Quick Ratio

1.04x

Div Yield

—

Div Rate

—

Div Growth 1Y

+12.67%

EarningsView details →

EPS (Actual)

−CNY 0.12

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

CNY 0.00

Avg Surprise (4Q)

—

Rev Surprise

0.00%

Financials snapshotView financials →

Revenue (TTM)

590.13M

Net Income (TTM)

−267.12M

Op. CF (TTM)

318.70M

Next earningsOct 26, 2026 →

Latest newsMore news →

Baike Biological announced its 2026 first-half results: net loss attributable to shareholders narrowed to 52.1001 million yuan from 73.5734 million yuan a year earlier, with revenue up 6.89% to 305 million yuan.31d ago

Similar companies

康缘药业600557.SH Sihuan Pharmaceutical Holdings Group Ltd.00460.HK 亚虹医药-U688176.SH Lantheus Holdings, Inc.LNTH 中牧股份600195.SH CanSino Biologics Inc.06185.HK Find similar companies →

Latest newsMore news →

Baike Biological announced its 2026 first-half results: net loss attributable to shareholders narrowed to 52.1001 million yuan from 73.5734 million yuan a year earlier, with revenue up 6.89% to 305 million yuan.31d ago